| Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study HÇ Yıldırım, E Mutlu, E Chalabiyev, M Özen, M Keskinkılıç, S Ön, A Çelebi, ... The Breast 66, 85-88, 2022 | 7 | 2022 |
| Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events İD Onur, E Mutlu, E Sertesen, T Önder, AO Duran, M İnanç Immunotherapy 16 (5), 295-303, 2024 | 1 | 2024 |
| The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer … HÇ Yıldırım, Y Kutlu, E Mutlu, MB Aykan, M Korkmaz, S Yalçın, T Şakalar, ... International Journal of Clinical Oncology, 1-8, 2024 | 1 | 2024 |
| The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey A Akyildiz, DC Guven, AA Ozluk, R Ismayilov, E Mutlu, OU Unal, I Yildiz, ... Medicine 102 (45), e35950, 2023 | 1 | 2023 |
| Prognostic significance of inflammation scores in malignant mesothelioma. E Mutlu, M Inanc European Review for Medical & Pharmacological Sciences 28 (6), 2024 | | 2024 |
| The effect of albumin to alkaline phosphatase ratio on survival in patients with metastatic bone sarcomas E Mutlu, O Bozkurt, M İnanç, M Ozkan, ST Fırat, R Coşar, İ Buğday, ... Hitit Medical Journal 6 (1), 71-78, 2024 | | 2024 |
| 71P The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast … HC Yildirim, Y Kutlu, E Mutlu, MB Aykan, M Korkmaz, S Yalcin, T Sakalar, ... ESMO Open 9, 2024 | | 2024 |
| 443P Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer C Karacin, F Aslan, A Dumludag, A Alkan, M Türker, KB Yucel, E Mutlu, ... Annals of Oncology 34, S368, 2023 | | 2023 |
| Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report E Mutlu, M Özkan, ST Fırat, R Coşar Journal of Clinical Practice and Research 45 (1), 101, 2023 | | 2023 |
| Sitogenetik Hasar Böbrek Nakli Hastalarında Malignite Gelişimi İçin Bir Biyobelirteç Midir? E Mutlu, A Ünal, A Kiraz, A Tasdemir, TD Ünal, İ Koçyiğit, M Sipahioğlu, ... Hipokrat Tıp Dergisi 2 (1), 6-13, 2022 | | 2022 |
| Nadir Tümörler AM SEDEF Akademisyen Kitabevi, 2022 | | 2022 |
| Risk factors for 30-day mortality in patients with cancer and COVID-19 in Turkey: A single center retrospective study E Mutlu, ST Firat, M Inanc, O Bozkurt, R Cosar, M Ozkan | | 2022 |
| Böbrek nakli hastalarında genetik hasarın incelenmesi E Mutlu Tıp Fakültesi, 0 | | |
| Is Cytogenetic Damage a Biomarker for The Risk of Malignancy Development In Renal Transplantation Patients? E MUTLU, A ÜNAL, A KİRAZ, A TAŞDEMİR, TDK ÜNAL, İ KOÇYİGİT, ... | | |
